Spark Therapeutics (NASDAQ:ONCE) had its target price reduced by investment analysts at Chardan Capital from $100.00 to $60.00 in a research note issued to investors on Tuesday. The firm currently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price target indicates a potential upside of 32.58% from the stock’s current price.

A number of other analysts have also commented on the company. BMO Capital Markets set a $73.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a report on Tuesday. Leerink Swann lowered Spark Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday. UBS lowered Spark Therapeutics from a “buy” rating to a “neutral” rating and set a $51.00 target price for the company. in a report on Tuesday. Cantor Fitzgerald set a $105.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a report on Monday. Finally, Raymond James Financial reissued a “buy” rating and issued a $75.00 target price on shares of Spark Therapeutics in a report on Thursday, December 7th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $83.75.

Spark Therapeutics (NASDAQ ONCE) traded down $2.46 during mid-day trading on Tuesday, reaching $45.26. The company had a trading volume of 1,613,121 shares, compared to its average volume of 459,444. Spark Therapeutics has a one year low of $41.06 and a one year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The company had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm’s quarterly revenue was up 45.8% on a year-over-year basis. During the same period last year, the business earned ($1.07) EPS. equities analysts forecast that Spark Therapeutics will post -7.6 earnings per share for the current year.

In other news, CFO Stephen W. Webster sold 10,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $70.14, for a total value of $701,400.00. Following the transaction, the chief financial officer now directly owns 12,500 shares in the company, valued at approximately $876,750. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total value of $356,600.00. Following the completion of the transaction, the insider now owns 215,000 shares in the company, valued at $15,333,800. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,068,809 shares of company stock worth $89,809,385. Company insiders own 7.30% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in shares of Spark Therapeutics by 15.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after buying an additional 241,016 shares during the last quarter. BlackRock Inc. lifted its position in Spark Therapeutics by 11.6% during the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after purchasing an additional 213,520 shares in the last quarter. Amundi Pioneer Asset Management Inc. purchased a new position in Spark Therapeutics during the third quarter valued at $5,286,000. TIAA CREF Investment Management LLC lifted its position in Spark Therapeutics by 20.3% during the second quarter. TIAA CREF Investment Management LLC now owns 62,480 shares of the biotechnology company’s stock valued at $3,733,000 after purchasing an additional 10,544 shares in the last quarter. Finally, Balyasny Asset Management LLC lifted its position in Spark Therapeutics by 104.8% during the second quarter. Balyasny Asset Management LLC now owns 59,400 shares of the biotechnology company’s stock valued at $3,549,000 after purchasing an additional 30,400 shares in the last quarter. Hedge funds and other institutional investors own 94.94% of the company’s stock.

WARNING: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/12/chardan-capital-lowers-spark-therapeutics-once-price-target-to-60-00.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.